The latest price target for Amneal Pharmaceuticals (NASDAQ:AMRX) was reported by Truist Securities on March 2, 2026. The analyst firm set a price target for $17.00 expecting AMRX to rise to within 12 months (a possible 43.70% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Amneal Pharmaceuticals (NASDAQ:AMRX) was provided by Truist Securities, and Amneal Pharmaceuticals maintained their buy rating.

The last upgrade for Amneal Pharmaceuticals Inc happened on February 24, 2025 when JP Morgan raised their price target to $12. JP Morgan previously had a neutral for Amneal Pharmaceuticals Inc.

There is no last downgrade for Amneal Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amneal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amneal Pharmaceuticals was filed on March 2, 2026 so you should expect the next rating to be made available sometime around March 2, 2027.

While ratings are subjective and will change, the latest Amneal Pharmaceuticals (AMRX) rating was a maintained with a price target of $15.00 to $17.00. The current price Amneal Pharmaceuticals (AMRX) is trading at is $11.83, which is out of the analyst’s predicted range.